CN108926716A - A kind of composition and its preparation method and application with Lyotropic Liquid Crystals - Google Patents
A kind of composition and its preparation method and application with Lyotropic Liquid Crystals Download PDFInfo
- Publication number
- CN108926716A CN108926716A CN201810741703.8A CN201810741703A CN108926716A CN 108926716 A CN108926716 A CN 108926716A CN 201810741703 A CN201810741703 A CN 201810741703A CN 108926716 A CN108926716 A CN 108926716A
- Authority
- CN
- China
- Prior art keywords
- composition
- water
- lecithin
- ethyl oleate
- liquid crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 239000004973 liquid crystal related substance Substances 0.000 title claims abstract description 45
- 230000002535 lyotropic effect Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 29
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 29
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 29
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 29
- 239000000787 lecithin Substances 0.000 claims abstract description 29
- 229940067606 lecithin Drugs 0.000 claims abstract description 29
- 235000010445 lecithin Nutrition 0.000 claims abstract description 29
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 239000003643 water by type Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000009466 transformation Effects 0.000 abstract description 7
- 230000010287 polarization Effects 0.000 description 24
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 16
- 230000008859 change Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 229960004063 propylene glycol Drugs 0.000 description 10
- 230000007704 transition Effects 0.000 description 9
- 235000012754 curcumin Nutrition 0.000 description 8
- 229940109262 curcumin Drugs 0.000 description 8
- 239000004148 curcumin Substances 0.000 description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 8
- 238000004455 differential thermal analysis Methods 0.000 description 6
- 238000010792 warming Methods 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- -1 oleic acid Ethyl ester -1,2- propylene glycol Chemical compound 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a kind of composition and its preparation method and application with Lyotropic Liquid Crystals, and the composition is mutually made of with water lecithin, oil；Wherein, the oil is mutually the uniform object that ethyl oleate and 1,2-PD obtain after mixing.The composition have liquid crystal structure, especially have stable liquid crystal structure, can wider temperature range such as at 25 to 70 DEG C in the range of keep stablize, be not susceptible to phase transformation.
Description
Technical field
The present invention relates to physical chemistry fields, and in particular to a kind of with the composition of Lyotropic Liquid Crystals and its preparation side
Method and application.
Background technique
Surfactant amphipathic molecule can form the ordered aggregation of various structures in water, comprising micella, vesica,
Microemulsion, lysotropic liquid crystal etc., wherein lysotropic liquid crystal is received significant attention because of various structures.Lysotropic liquid crystal (LLC), is by amphipathic
Long-range order that molecule is formed in a solvent and the unordered aggregated structure of short distance, common liquid crystal structure type mainly have lamellar phase
Liquid crystal, hexagonal liquid crystal and Cubic Lyotropic Liquid Crystals.Lysotropic liquid crystal is used as the carrier of a variety of drugs, molten cause due to own structural characteristics
Hydrophilic area in liquid crystal can dissolve water soluble compound, and hydrophobic region can dissolve some lyophobic dusts, can be realized pair
The solubilising of insoluble drug and the slow release of drug, it may be said that their unique structures, thermodynamic stability and bipolarity/non-
It is specific that height may be implemented in addition phase geometry or symmetry carry out brilliant a possibility that controlling to structural parameters in polar character
Application, therefore obtained extensive concern in medicine and field of food, following application field also will be more and more wide.
But presently, there are Lyotropic Liquid Crystals stability it is bad, be easy with temperature variation and undergo phase transition,
And often there are multiple phase transition temperatures closed on, so that the equilibrium temperature narrow limits of lysotropic liquid crystal, are unfavorable in chemicals
And it is applied in pharmaceuticals.
Summary of the invention
Therefore, the purpose of the present invention is to provide a kind of stable ternary compositions, with liquid crystal structure, especially have steady
Fixed Lyotropic Liquid Crystals such as more excellent in wider temperature range can keep steady in the range of 25 to 70 DEG C
It is fixed, it is not susceptible to phase transformation, can be used as the carrier of the oil-soluble medicines such as curcumin, the means of transportation of original new drug and realize drug
Slow release.
The present invention is achieved through the following technical solutions.
Firstly, being mutually made of with water the present invention provides a kind of composition lecithin, oil；
Wherein, the oil is mutually the uniform object that ethyl oleate and 1,2-PD obtain after mixing；
Preferably, the mass ratio of the ethyl oleate and 1,2-PD is 1:1；
Preferably, the composition is 43.48-80.11%, water content 19.89- in its lecithin content
56.52wt%, and when maximum oil phase content is not higher than 50wt% is mesomorphic state, wherein the percentage composition of each component it
Be no more than 100%；
Preferably, the liquid crystal is lysotropic liquid crystal, i.e., the described composition has Lyotropic Liquid Crystals.
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase no more than 30wt% and 10-
The water of 40wt%, wherein the sum of percentage composition of each component is no more than 100%；
Preferably, in the composition, the content of lecithin is 50-60wt%, preferably 50wt% or 60wt%；
Preferably, in the composition, the content of oily phase is 10-30wt%, preferably 20-30wt%, more preferably
20wt%；
Preferably, in the composition, the content of water is 10-30wt%, preferably 12-30wt%, more preferably 20-
30wt%, most preferably 30wt%.
Preferably, the phase boundray temperature of the composition is higher than 40 DEG C, preferably higher than 58 DEG C, more preferably higher than 60 DEG C, most
It is preferred that between 60-80 DEG C；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 20-30wt% and 10-30wt%
Water, wherein the sum of percentage composition of each component is no more than 100%；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 20wt% and the water of 12-30wt%,
Wherein, the sum of described each component percentage composition is no more than 100%；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 30wt% and the water of 10-30wt%,
Wherein, the sum of described each component percentage composition is no more than 100%.
Preferably, the content of each component is as shown in Figure 1 in the composition.
Secondly, the present invention provides a kind of methods for preparing above-mentioned composition, which comprises
(1) it will be uniformly mixed after ethyl oleate and 1,2-PD accurate weighing with eddy mixer, it is mutually equal to obtain oil
Even object；
(2) lecithin and oily phase are weighed respectively, are added in the colorimetric cylinder with plug, are sufficiently stirred under 60-70 DEG C of water-bath
It is uniformly mixed, secondary distilled water is added into colorimetric cylinder；After being thoroughly mixed uniformly, about 10 minutes left sides are centrifuged using centrifuge
Then the right side balances 7 angel's liquid crystal structures in 25 DEG C of waters bath with thermostatic control and reaches balance to remove bubble removing.
Preferably, in the step (1), ethyl oleate and 1,2-PD are mixed with the mass ratio of 1:1, obtain oleic acid
Ethyl ester -1,2- propylene glycol oil phase object.
Preferably, in the step (2), the distilled water selection is added dropwise, and the amount of distilled water is controlled with 2-
The interval of 4wt% increases, and time interval is 15 minutes.
In addition, the present invention also provides above-mentioned composition prepare chemicals, the application in pharmaceuticals.
Preferably, the composition can be used as the carrier of oil-soluble medicine, or means of transportation or use as original new drug
Make the skeleton of medicament slow release；The oil-soluble medicine or the original new drug delay with the destruction of composition Lyotropic Liquid Crystals
On The Drug Release, to realize the protection to drug or the transport to drug or realize the sustained release to drug.
For example, in a specific embodiment, the present invention can be used as the pharmaceutical carrier of turmeric, curcumin is dissolved in 1,
In 2- propylene glycol, uniform object is collectively formed with ethyl oleate, that is, forms the ethyl oleate -1,2-PD for containing curcumin
(1:1) oil phase, then the method according to the invention participates in constructing for Lyotropic Liquid Crystals jointly, forms the molten cause for containing curcumin
Liquid crystal.
Curcumin has the effects that reducing blood lipid, antitumor, anti-inflammatory, cholagogue, anti-oxidant.It finds in practical applications, turmeric
There are certain defects for element, if solubility is not high, stability is poor, absorptivity is low, be easily converted in enteron aisle glucoside aldehydic acid and
The compounds such as sulfonic acid, metabolism is fast, half-life short, and it is lower that the presence of these problems results in its bioavilability, limit its
Application in food and medicine field.This application not only can solve the solubility of curcumin, but also can be in the body of drug
Curcumin is preferably protected in interior transportational process, avoids curcumin from being converted into glucoside aldehydic acid and sulfonic acid etc. in enteron aisle compound
Object.
Detailed description of the invention
Hereinafter, carrying out the embodiment that the present invention will be described in detail in conjunction with attached drawing, in which:
Lecithin/ethyl oleate -1,2-PD/water ternary system phasor when Fig. 1 is 37 DEG C, wherein LC indicates single
Phase liquid crystal area, B1, B2, B3, B4, B5, B6 are six sample spots selected in liquid crystal region；
Fig. 2 is the situation of change that composition S1 increases polarization texture with temperature, wherein polarisation line when Fig. 2A is 25 DEG C
Reason, polarization texture when Fig. 2 B is 40 DEG C, polarization texture when Fig. 2 C is 70 DEG C；
Fig. 3 is the situation of change that composition S2 increases polarization texture with temperature, wherein polarisation line when Fig. 3 A is 25 DEG C
Reason, polarization texture when Fig. 3 B is 45 DEG C, polarization texture when Fig. 3 C is 75 DEG C；
Fig. 4 is the situation of change that composition S3 increases polarization texture with temperature, wherein polarisation line when Fig. 4 A is 25 DEG C
Reason, polarization texture when Fig. 4 B is 45 DEG C, polarization texture when Fig. 4 C is 75 DEG C；
Fig. 5 is the situation of change that composition S4 increases polarization texture with temperature, wherein polarisation line when Fig. 5 A is 30 DEG C
Reason, polarization texture when Fig. 5 B is 60 DEG C, polarization texture when Fig. 5 C is 70 DEG C；
Fig. 6 is the situation of change that composition S5 increases polarization texture with temperature, wherein polarisation line when Fig. 6 A is 25 DEG C
Reason, polarization texture when Fig. 6 B is 45 DEG C, polarization texture when Fig. 6 C is 70 DEG C；
Fig. 7 is the situation of change that composition S6 increases polarization texture with temperature, wherein polarisation line when Fig. 7 A is 25 DEG C
Reason, polarization texture when Fig. 7 B is 45 DEG C, polarization texture when Fig. 7 C is 70 DEG C；
Fig. 8 is the differential thermal analysis DTA curve of composition S1；
Fig. 9 is the differential thermal analysis DTA curve of composition S2；
Figure 10 is the differential thermal analysis DTA curve of composition S3；
Figure 11 is the differential thermal analysis DTA curve of composition S4；
Figure 12 is the differential thermal analysis DTA curve of composition S5；
Figure 13 is the DTA curve of composition S6.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part or according to the normal condition proposed by manufacturer.
Unless otherwise defined, it anticipates known to all professional and scientific terms as used herein and one skilled in the art
Justice is identical.In addition, any method similar to or equal to what is recorded and material can be applied to the method for the present invention.Wen Zhong
The preferred implement methods and materials are for illustrative purposes only.
Drug and instrument:
Lecithin: AlfaAesar (China) Chemical Co., Ltd.；
Ethyl oleate: chemical pure, Sinopharm Chemical Reagent Co., Ltd.；
1,2-PD: pure, Sinopharm Chemical Reagent Co., Ltd. is analyzed；
XH-T vortex mixer: Jiangsu Jin Yi instrument Science and Technology Ltd.；
Low speed desk centrifuge: Anting Scientific Instrument Factory, Shanghai；
AR124CN electronic balance: Ohaus Instrument (Changzhou) Co., Ltd.；
ZCR differential thermal analyzer: Nanjing Sang Li Electronic Equipment Factory；
Magnetic stirring apparatus: DF-101S heat collecting type constant-temperature heating magnetic stirring apparatus
SZ-93A dual pure water distiller automatically: Shanghai Yarong Biochemical Instrument Plant.
1 lecithin of embodiment/ethyl oleate -1,2- propylene glycol (1:1)/water ternary system phasor drafting
It is uniformly mixed and is obtained with eddy mixer after ethyl oleate and 1,2- propylene glycol are weighed accurately with the mass ratio of 1:1
The uniform object of ethyl oleate -1,2-PD weighs lecithin and the uniform object of ethyl oleate -1,2-PD, mass ratio respectively
Change to 0:10 with 10:0, be added in the colorimetric cylinder with plug, be thoroughly mixed under 60-70 DEG C of water-bath uniformly, to than
Secondary distilled water is added dropwise in colour tube, the mass percent of secondary distilled water is increased with the interval of 2-4%, time interval 15
Minute.The colorimetric cylinder for filling sample is placed in 37 DEG C of waters bath with thermostatic control after being thoroughly mixed uniformly and balances at least 30 minutes to reaching
To balancing each other, need that equilibration time is appropriately extended when close to phase boundray, sample, that is, lecithin/ethyl oleate-after balance
1,2- propylene glycol (1:1)/water ternary system composition.
Wherein, lecithin/ethyl oleate -1,2-PD (1:1)/water ternary system phasor is as shown in Figure 1.Such as Fig. 1 institute
Show, when lecithin content is 43.48-80.11%, water content 19.89-56.52wt% in three-phase system, maximum oil capacity is
There is liquid crystal region in (the sum of three's percentage composition is no more than 100%) in the range of 50wt%, in content range as shown in Figure 1
The combination of interior ingredient has liquid crystal structure.
The preparation of 2 composition of embodiment
In lecithin/ethyl oleate -1,2- propylene glycol (1:1)/water ternary system mixture liquid crystal prepared by embodiment 1
Six sample spots of regional choice (i.e. B1, B2, B3, B4, B5, B6, as shown in Figure 1), according to Fig. 1,6 sample spots have such as
Composition and content shown in table 1.
Weighing lecithin and oily phase respectively by composition and content shown in table 1, (i.e. ethyl oleate -1,2- propylene glycol (1:1) is equal
Even object, by being uniformly mixed after weighing ethyl oleate and 1,2-PD accurately with the mass ratio of 1:1 with eddy mixer
Obtain) after be put into colorimetric cylinder, be thoroughly mixed under 60-70 DEG C of water-bath uniformly, be added dropwise into colorimetric cylinder secondary
The mass percent of distilled water, secondary distilled water is increased with the interval of 2-4%, and time interval is 15 minutes.Using centrifuge from
To remove bubble removing, 7 angel's liquid crystal structures are then balanced under 25 DEG C of water-baths and reach balance within the heart about 10 minutes or so, respectively obtain this
Composition S1, S2, S3, S4, S5 and S6 of invention.
The composition and content of 1 composition S1~S6 of table
The measurement of 3 polarization texture of embodiment
Load is made in the composition S1~S6 prepared in embodiment 2, using constant temperature water bath apparatus respectively as shown in table 2
At a temperature of balance 15 minutes, observe polarization texture using BK-POL petrographic microscope, correlated digital photo utilizes and electricity
The camera shooting of the OPTEC TP DV500 of brain connection, as a result as illustrated in figs. 2-7.
The equilibrium temperature of 2 composition S1~S6 of table
Interpretation of result:
Composition S1 is finer and close texture (as shown in Figure 2 A) at 25 DEG C, is increased to about 40 DEG C with temperature, polarisation
Texture tends to be sparse (as shown in Figure 2 B), is continuously heating to about 70 DEG C or so (higher than the 60 DEG C) texture of appearance than comparatively dense again
(as shown in Figure 2 C) illustrates the generation for having phase transformation as the temperature rises；
Composition S2 rises to about 45 DEG C or so by 25 DEG C in temperature, and polarization texture varies slightly, but be not it is particularly evident (such as
Shown in Fig. 3 A and Fig. 3 B), about 75 DEG C or so are warming up to, large change (as shown in Figure 3 C) occurs in liquid crystal texture；
Composition S3 is then warming up to 60 DEG C being warming up to 40 DEG C by 25 DEG C, as shown in Figure 4 A and 4 B shown in FIG., polarisation does not occur
Texture variations, liquid crystal structure is relatively stable, but changes (as shown in Figure 4 C) in 75 DEG C or so polarization textures, illustrates there is phase transformation
Occur；
Composition S4 is at 30 DEG C, as shown in Figure 5A, it can be seen that is similar to layered liquid crystal cruciate flower texture, is warming up to 45
DEG C 60 DEG C are then warming up to, as shown in Figure 5 B, polarization texture changes, until about 70 DEG C have more complete phase transformation (such as Fig. 5 C
It is shown).
Composition S5 is started to warm up by 25 DEG C, and polarization texture is almost without significant change (as shown in Figure 6 A and 6 B), and 70 DEG C
Front and back has phase transition that (as shown in Figure 6 C) occurs.
Composition S6 is proceeded between about 60 DEG C at 25 DEG C to 45 DEG C, and liquid crystal structure is more stable (such as Fig. 7 A and Fig. 7 B institute
Show), but layered liquid crystal cruciate flower texture is had found in 70 DEG C of polarisation photo (as seen in figure 7 c), phase transformation clearly has occurred.
The measurement of embodiment 4DTA
The chemical changes such as phase transition, crystalline texture transformation and destruction lattice structure can all cause fuel factor, generate enthalpy change, because
This, we measure the enthalpy change effect of composition S1~S6 using DTA, and instrument is ZCR differential thermal analyzer, as a result such as Fig. 8-
Shown in 13.
Interpretation of result:
There are two sharp absorption peaks (as shown in Figure 8) by composition S1, and phase boundray temperature is respectively at 41.2 DEG C and 60.4
DEG C or so, i.e., in two temperature, the structure of lysotropic liquid crystal starts to be destroyed；The phase transition temperature of composition S2 at 42.8 DEG C and
74.8 DEG C or so；The phase transition temperature of composition S3 is at 59.6 DEG C or so；The phase transition temperature of composition S4 is at 66 DEG C or so；Composition
The phase transition temperature of S5 is at 77 DEG C or so；Result that the phase transition temperature of composition S6 is obtained at 68 DEG C or so, by differential thermal analysis and partially
Light experiment substantially conforms to.
Embodiment 5
Lecithin 68wt%, ethyl oleate 10wt%, 1,2-PD 10wt% are weighed respectively, under 60-70 DEG C of water-bath
It is thoroughly mixed uniformly, secondary distilled water is added dropwise into colorimetric cylinder, the mass percent of secondary distilled water is with 2-4%'s
Interval increases, and time interval is 15 minutes；After being thoroughly mixed uniformly, it is added in the colorimetric cylinder with plug, 60-70 DEG C of water
It is thoroughly mixed under bath uniformly, is centrifuged about 10 minutes or so to remove bubble removing, then in 25 DEG C of waters bath with thermostatic control using centrifuge
Middle balance 7 days, obtains composition S7.Through detecting, composition S7 is microemulsion, and not formed Lyotropic Liquid Crystals.
Embodiment 6
It is uniformly mixed and is obtained with eddy mixer after ethyl oleate and 1,2- propylene glycol are weighed accurately with the mass ratio of 1:1
The uniform object of ethyl oleate -1,2- propylene glycol；Lecithin 68wt%, ethyl oleate -1,2- propylene glycol (1:1) are weighed respectively
20wt%, secondary distilled water 12wt% are added in the colorimetric cylinder with plug, are thoroughly mixed under 60-70 DEG C of water-bath
It is even, about 10 minutes or so are centrifuged to remove bubble removing using centrifuge, are then balanced 7 days, are combined in 25 DEG C of waters bath with thermostatic control
Object S8, through detecting, composition S8 is microemulsion, and not formed Lyotropic Liquid Crystals.
Embodiment 7
It is uniformly mixed after ethyl oleate and 1,2- propylene glycol are weighed accurately with the mass ratio of 1:1.2 with eddy mixer
To the uniform object of ethyl oleate -1,2-PD, lecithin and the uniform object of ethyl oleate -1,2-PD are weighed respectively, 60-70 DEG C
Water-bath under be thoroughly mixed uniformly, secondary distilled water, the mass percent of secondary distilled water are added dropwise into colorimetric cylinder
Increased with the interval of 2-4%, time interval is 15 minutes；After being thoroughly mixed uniformly, it is added in the colorimetric cylinder with plug,
It is thoroughly mixed under 60-70 DEG C of water-bath uniformly, is centrifuged about 10 minutes or so to remove bubble removing, then 25 using centrifuge
It is balanced 7 days in DEG C water bath with thermostatic control, obtains composition S9.Through detecting, composition S7 is microemulsion, and not formed lysotropic liquid crystal knot
Structure.
Claims (9)
1. a kind of composition is mutually made of with water lecithin, oil；Wherein, the oil is mutually ethyl oleate and 1,2-PD
The uniform object obtained after mixing.
2. composition according to claim 1, which is characterized in that the mass ratio of the ethyl oleate and 1,2-PD is
1:1。
3. composition according to claim 1 or 2, which is characterized in that the composition is in its lecithin content
43.48-80.11%, water content 19.89-56.52wt%, and when maximum oil phase content is not higher than 50wt% is mesomorphic state,
Wherein, the sum of percentage composition of each component is no more than 100%；
Preferably, the liquid crystal is lysotropic liquid crystal, i.e., the described composition has Lyotropic Liquid Crystals.
4. composition according to any one of claim 1 to 3, which is characterized in that the composition contains 50-68wt%
Lecithin, no more than 30wt% oil mutually and 10-40wt% water, wherein the sum of described each component percentage composition does not surpass
Cross 100%；
Preferably, in the composition, the content of lecithin is 50-60wt%, preferably 50wt% or 60wt%；
Preferably, in the composition, the content of oily phase is 10-30wt%, preferably 20-30wt%, more preferably 20wt%；
Preferably, in the composition, the content of water is 10-30wt%, preferably 12-30wt%, more preferably 20-
30wt%, most preferably 30wt%；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 20-30wt% and the water of 10-30wt%,
Wherein, the sum of described each component percentage composition is no more than 100%；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 20wt% and the water of 12-30wt%,
In, the sum of described each component percentage composition is no more than 100%；
Preferably, the composition contains the lecithin of 50-68wt%, the oil phase of 30wt% and the water of 10-30wt%,
In, the sum of described each component percentage composition is no more than 100%.
5. composition according to any one of claim 1 to 4, which is characterized in that the composition to boundary temperature
It is being higher than 40 DEG C, preferably higher than 58 DEG C, more preferably higher than 60 degrees Celsius, most preferably between 60-80 DEG C.
6. a kind of method for preparing composition described in any one of claims 1 to 5, which comprises
(1) it will be uniformly mixed after ethyl oleate and 1,2-PD accurate weighing with eddy mixer, to obtain oily phase；
(2) lecithin and oily phase are weighed respectively, are added in the colorimetric cylinder with plug, are thoroughly mixed under 60-70 DEG C of water-bath
Uniformly, secondary distilled water is added into colorimetric cylinder；It after being thoroughly mixed uniformly, is centrifuged using centrifuge, is preferably centrifuged 10 points
Then clock is balanced with removing bubble removing in 25 DEG C of waters bath with thermostatic control, preferably balance 7 angel's liquid crystal structures and reach balance.
7. according to the method described in claim 4, it is characterized in that, in the step (1), ethyl oleate and 1,2-PD
It is mixed with the mass ratio of 1:1, obtains ethyl oleate -1,2-PD oil phase thing.
8. according to the method described in claim 4, it is characterized in that, the distilled water selection adds dropwise in the step (2)
Enter, in the interval increase with 2-4wt%, time interval is 15 minutes for the amount control of distilled water.
9. composition described in any one of claims 1 to 5 prepare cosmetics, the application in pharmaceuticals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810741703.8A CN108926716B (en) | 2018-07-06 | 2018-07-06 | Composition with lyotropic liquid crystal structure and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810741703.8A CN108926716B (en) | 2018-07-06 | 2018-07-06 | Composition with lyotropic liquid crystal structure and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108926716A true CN108926716A (en) | 2018-12-04 |
| CN108926716B CN108926716B (en) | 2021-07-20 |
Family
ID=64447894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810741703.8A Active CN108926716B (en) | 2018-07-06 | 2018-07-06 | Composition with lyotropic liquid crystal structure and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108926716B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589301A (en) * | 2018-12-20 | 2019-04-09 | 山东师范大学 | A kind of the sustained release aggregation and preparation method of the apiolin with responsiveness |
| CN111939128A (en) * | 2020-08-19 | 2020-11-17 | 山东省分析测试中心 | Temperature-sensitive lyotropic liquid crystal drug carrier and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502485A (en) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | Nano cubic liquid crystal dexamethasone preparation for eye and preparation method thereof |
| CN105658196A (en) * | 2013-09-26 | 2016-06-08 | 科丝美诗株式会社 | Preparation method for multilayer lamellar liquid crystal emulsion containing intercellular lipid |
-
2018
- 2018-07-06 CN CN201810741703.8A patent/CN108926716B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502485A (en) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | Nano cubic liquid crystal dexamethasone preparation for eye and preparation method thereof |
| CN105658196A (en) * | 2013-09-26 | 2016-06-08 | 科丝美诗株式会社 | Preparation method for multilayer lamellar liquid crystal emulsion containing intercellular lipid |
Non-Patent Citations (2)
| Title |
|---|
| NILESH PATEL ETAL: ""Phospholipid-Based Microemulsions Suitable for Use in Foods"", 《J. AGRIC. FOOD CHEM.》 * |
| 魏玲: ""天然两亲分子缔合结构形成及对药物的保护作用"", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589301A (en) * | 2018-12-20 | 2019-04-09 | 山东师范大学 | A kind of the sustained release aggregation and preparation method of the apiolin with responsiveness |
| CN109589301B (en) * | 2018-12-20 | 2022-04-01 | 山东师范大学 | Apigenin slow-release aggregate with responsiveness and preparation method thereof |
| CN111939128A (en) * | 2020-08-19 | 2020-11-17 | 山东省分析测试中心 | Temperature-sensitive lyotropic liquid crystal drug carrier and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108926716B (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martins et al. | Insights into the nature of eutectic and deep eutectic mixtures | |
| Deckelbaum et al. | Structure and interactions of lipids in human plasma low density lipoproteins. | |
| Estep et al. | Studies on the anomalous thermotropic behavior of aqueous dispersions of dipalmitoylphosphatidylcholine-cholesterol mixtures | |
| CN108685767B (en) | Preparation method of oil-in-water type plukenetia volubilis linneo oil microemulsion | |
| Dong et al. | The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity | |
| Martino et al. | Improved dissolution behavior of fenbufen by spherical crystallization | |
| CN108926716A (en) | A kind of composition and its preparation method and application with Lyotropic Liquid Crystals | |
| Dave et al. | Mixed liquid crystals | |
| Tinberg et al. | Role of lipids in mitochondrial energy coupling: evidence from spin labeling and freeze-fracture electron microscopy | |
| CN108451894A (en) | A kind of curcumin carrier with temperature-responsive | |
| Weihs et al. | Biliary cholesterol crystallization characterized by single-crystal cryogenic electron diffraction | |
| Van der Gucht et al. | Multiple shear-banding transitions in a supramolecular polymer solution | |
| Epand et al. | A new high-temperature transition of crystalline cholesterol in mixtures with phosphatidylserine | |
| Mercado et al. | Solution thermodynamics of methocarbamol in some ethanol+ water mixtures | |
| Zheng et al. | Solvent dependent interactions between droplets in water-in-oil microemulsions | |
| Amenitsch et al. | Bile salts form lyotropic liquid crystals | |
| Jacobs et al. | Behavior of hexane dissolved in dimyristoylphosphatidylcholine bilayers: an NMR and calorimetric study | |
| Cui et al. | Analysis of competitive binding of ligands to human serum albumin using NMR relaxation measurements | |
| CN109169648A (en) | A kind of pyraclostrobin Pesticide Microemulsion preparation and preparation method | |
| McBain et al. | Phase rule studies of soap systems. I. applicability of the phase rule | |
| Enever | Correlation of phase inversion temperature with kinetics of globule coalescence for emulsions stabilized by a polyoxyethylene alkyl ether | |
| Guo et al. | Accurate quantification of hydration number for polyethylene glycol molecules | |
| CN114404325A (en) | Oil-in-water rapeseed oil microemulsion capable of being infinitely diluted, and preparation method and application thereof | |
| AL-SHAIBANI et al. | Design and characterization of candesartan cilexetil oral nanoemulsion containing garlic oil | |
| CN109125267B (en) | Preparation method and in-vitro release performance of lyotropic liquid crystal carrier with curcumin protection effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240318 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Country or region after: China Address before: 250014 No. 88 East Wenhua Road, Shandong, Ji'nan Patentee before: SHANDONG NORMAL University Country or region before: China |